News

Dr. Hai T. Vo, Ph.D. has joined DiscoveryBioMed, Inc. as a Senior Scientist

DiscoveryBioMed, Inc. is pleased to announce that Dr. Hai Vo has joined DBM as a senior scientist. “Dr. Vo has already proved to be a man of many scientific talents and capable of wearing multiple hats,” explained Dr. Schwiebert, DBM’s CEO and CSO. In particular, Hai will lead our efforts in extending our CRO services business capabilities into quantitative RT-PCR and protein biochemistry so as to assess key targets at the mRNA and protein level in both CRO services client projects and in our R&D humanized drug discovery programs. He is also learning the details and key steps in our medium-throughput screening campaigns. Hai received his Ph.D. from the University of Alabama at Birmingham in work focused on the protein, Klotho, in primary neurons and its multiple roles in cellular neurobiology.

Read More

DBM Increases Engagement with Scientists, Researchers, and Entrepreneurs

Going through the threshold from 2017 to 2018, DBM endeavored to increase its engagement and by extension its visibility within the larger biotechnology community. Now entering Q4 of 2018, we sit down with DBM’s Head of Business Development, Matthew Redmann, Ph.D., to discuss DBM’s efforts up until this point and what is planned for the remaining part of the year and into 2019. Q: Going into 2018, what have been your objectives from a business development perspective? A: Discovery BioMed has historically developed and maintained substantive and fruitful relationships with our many clients and collaborators with groups spread across the globe – in the U.S., Europe, and Asia. However, due to the nature of the work, most of it is shielded behind non-disclosures, making it difficult to organically create momentum. In 2018 we sought to change that by adopting a more pro-active approach to marketing our services and building relationships. Q: Given that key goal, what has been DBM’s strategy to achieve it? A: A lot can be accomplished just by reaching out to people...

Read More

The Birmingham Life Sciences and Biotechnology Ecosystem – DiscoveryBioMed, Inc. Has Been Helping this Ecosystem for 11 Years

Routinely, we read stories in the Birmingham Business Journal, the UAB Magazine, the Economic Development Partnership of Alabama news flashes and news releases and elsewhere about innovation and entrepreneurship. It is of high value to DiscoveryBioMed’s Dr. Schwiebert and it cannot be talked about enough. The Birmingham Business Alliance estimates that there are over 700 technology companies in the Birmingham metro. Having said all that and continuing to talk about that in multiple articles with quotes and sound bites and the like, a critical mass of life sciences and biotechnology companies is still struggling to materialize. “Innovation is an over-used word. Action with creativity and urgency is more critical,” declares DBM’s Dr. Schwiebert. That is why DiscoveryBioMed, Inc. has and is actively helping ‘hands on’ with creativity and urgency to help create a critical mass of life sciences and biotechnology companies in Birmingham. The list includes: Endomimetics, Soluble Therapeutics (now acquired), Vulcan Analytical, Blondin Biosciences, Reliant Glycosciences, CNine BioSolutions, Trialtus Biosciences, Nitor Therapeutics, Amytrx Therapeutics, Meridian Biotech, GLG Pharma, Sequela, Push PD, and others that...

Read More

An Extra Large “Thank You” to our Contract Research Organization (CRO) Services Clients

The period of 2017 and 2018 has realized a significant uptick in our CRO services business focused on diseased and normal human cell platform technology creation and in the use of diseased and normal human cells in bioassays profiling the lead therapeutic assets of industry and academic clients. “We thank very much the many clients that have made use of our diseased and normal human cell platform technology and that have entrusted us to perform bioassay profiling on lead therapeutic assets,” said Dr. Erik Schwiebert. “Moreover, this blossoming of this sector of our business correlates with the presence of DBM’s Head of Business Development, Dr. Matthew Redmann. He has been creative and tireless in targeting and identifying new clients.” DBM is under confidentiality agreement with the majority of its clients. But in the US, DBM has multiple clients and partners in the Boston area and San Francisco Bay Area, as well as in the San Diego and Los Angeles areas. We also have numerous clients in the Philadelphia area. In addition, we have smaller clients...

Read More

2018 – Diseased and Normal Human Cell Platform Technologies

DBM has found its niche in this above marketplace. DBM creates and establishes human cell platforms and designs and invents bioassays using the same human cell platforms as key ingredients. And even though it is a new year, DBM carries with it the same bedrock vision it held when the company was founded in 2007 – better results through leveraging diseased human cell platform technology. We look forward to continue to serve the biotechnology sector locally, regionally, nationally, and internationally with our expertise, know-how and innovative assays. Although many of our clients are confidential, we thank them all for their patronage. We are gratified to have extended work with many of them. We see an increased interest in ‘humanizing” drug discovery and profiling within industry and academia and DBM is gratified that our core principle is gaining traction among our clients and in the marketplace. DBM is proud to announce continued progress in one “Fast Track” SBIR award supported by the NIH ORIP focused on the creation of genotyped human ADPKD cell platforms and 3D...

Read More

2017 in Review – A Year of Growth and Addition of Key Team Members at DBM

As DBM reflects on a strong 2017 and hello to a promising 2018, DBM said hello to several new faces in both its labs and offices. In the past year, DBM has added new staff and new capabilities. In early 2017, DiscoveryBioMed hired Matthew Redmann, PhD to the post of Head of Business Development and Senior Scientist. As a recently graduated Ph.D. from the University of Alabama at Birmingham (UAB), Matthew brings with him a quality publication record and substantive interests in the business of science and how to translate discoveries at the bench to useful applications in the world. Matt is originally from Appleton, WI. Shortly after, Lawrence Greer, J.D., LLM was appointed as Chief Financial Officer to oversee and manage the increasing complexity of DBM’s financial dealings. Lawrence earned his J.D from the University of Alabama School of Law and brings with him significant legal and business experience in the biotechnology and finance realms. Lawrence is originally from Birmingham, AL. Alongside these additions, DBM promoted a long-term and valued intern, Albert “Os” Nakayama,...

Read More